These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 9266417

  • 1. Cop 1 as a candidate drug for multiple sclerosis.
    Teitelbaum D, Arnon R, Sela M.
    J Neural Transm Suppl; 1997; 49():85-91. PubMed ID: 9266417
    [Abstract] [Full Text] [Related]

  • 2. Copolymer 1: from basic research to clinical application.
    Teitelbaum D, Arnon R, Sela M.
    Cell Mol Life Sci; 1997 Jan; 53(1):24-8. PubMed ID: 9117994
    [Abstract] [Full Text] [Related]

  • 3. Specific vaccines against autoimmune diseases.
    Sela M.
    C R Acad Sci III; 1999 Nov; 322(11):933-8. PubMed ID: 10646086
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.
    Arnon R, Sela M, Teitelbaum D.
    J Neurol; 1996 Apr; 243(4 Suppl 1):S8-13. PubMed ID: 8965119
    [Abstract] [Full Text] [Related]

  • 6. Immunomodulation by the copolymer glatiramer acetate.
    Arnon R, Sela M.
    J Mol Recognit; 2003 Apr; 16(6):412-21. PubMed ID: 14732933
    [Abstract] [Full Text] [Related]

  • 7. [Clinical trial of copolymer 1 in multiple sclerosis].
    Teitelbaum D, Arnon R, Sela M, Abramsky O.
    Harefuah; 1989 May 01; 116(9):453-6. PubMed ID: 2680816
    [Abstract] [Full Text] [Related]

  • 8. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.
    Aharoni R, Teitelbaum D, Arnon R, Sela M.
    Proc Natl Acad Sci U S A; 1999 Jan 19; 96(2):634-9. PubMed ID: 9892685
    [Abstract] [Full Text] [Related]

  • 9. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.
    Aharoni R, Teitelbaum D, Sela M, Arnon R.
    Proc Natl Acad Sci U S A; 1997 Sep 30; 94(20):10821-6. PubMed ID: 9380718
    [Abstract] [Full Text] [Related]

  • 10. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.
    Aharoni R, Teitelbaum D, Sela M, Arnon R.
    J Neuroimmunol; 1998 Nov 02; 91(1-2):135-46. PubMed ID: 9846830
    [Abstract] [Full Text] [Related]

  • 11. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.
    Teitelbaum D, Arnon R, Sela M.
    Proc Natl Acad Sci U S A; 1999 Mar 30; 96(7):3842-7. PubMed ID: 10097125
    [Abstract] [Full Text] [Related]

  • 12. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE).
    Lisak RP, Zweiman B, Blanchard N, Rorke LB.
    J Neurol Sci; 1983 Dec 30; 62(1-3):281-93. PubMed ID: 6199466
    [Abstract] [Full Text] [Related]

  • 13. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses.
    Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M.
    J Neuroimmunol; 1996 Feb 30; 64(2):209-17. PubMed ID: 8632064
    [Abstract] [Full Text] [Related]

  • 14. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.
    Teitelbaum D, Brenner T, Abramsky O, Aharoni R, Sela M, Arnon R.
    Mult Scler; 2003 Dec 30; 9(6):592-9. PubMed ID: 14664472
    [Abstract] [Full Text] [Related]

  • 15. Suppression of experimental allergic encephalomyelitis by COP1--relevance to multiple sclerosis.
    Arnon R, Teitelbaum D, Sela M.
    Isr J Med Sci; 1989 Dec 30; 25(12):686-9. PubMed ID: 2533187
    [Abstract] [Full Text] [Related]

  • 16. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.
    Fridkis-Hareli M, Santambrogio L, Stern JN, Fugger L, Brosnan C, Strominger JL.
    J Clin Invest; 2002 Jun 30; 109(12):1635-43. PubMed ID: 12070311
    [Abstract] [Full Text] [Related]

  • 17. The concept of specific immune treatment against autoimmune diseases.
    Sela M.
    Int Rev Immunol; 1999 Jun 30; 18(3):201-16. PubMed ID: 10614724
    [Abstract] [Full Text] [Related]

  • 18. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
    Teitelbaum D, Aharoni R, Klinger E, Kreitman R, Raymond E, Malley A, Shofti R, Sela M, Arnon R.
    Ann N Y Acad Sci; 2004 Dec 30; 1029():239-49. PubMed ID: 15681762
    [Abstract] [Full Text] [Related]

  • 19. Glatiramer acetate in the treatment of multiple sclerosis.
    Sela M, Teitelbaum D.
    Expert Opin Pharmacother; 2001 Jul 30; 2(7):1149-65. PubMed ID: 11583066
    [Abstract] [Full Text] [Related]

  • 20. Early pregnancy factor suppresses experimental autoimmune encephalomyelitis induced in Lewis rats with myelin basic protein and in SJL/J mice with myelin proteolipid protein peptide 139-151.
    Zhang B, Harness J, Somodevilla-Torres MJ, Hillyard NC, Mould AW, Alewood D, Love SG, Alewood PF, Greer JM, Cavanagh AC, McCombe PA, Morton H.
    J Neurol Sci; 2000 Dec 15; 182(1):5-15. PubMed ID: 11102634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.